Ibritumomab Tiuxetan (Systemic)

Brand Names : Zevalin, IDEC-2B8 (ibritumomab tiuxetan), IDEC-Y2B8 (yttrium-90–ibritumomab tiuxetan), IDEC-In2B8 (indium-111–ibritumomab tiuxetan), IDEC-129

Category

• Monoclonal antibody
• antineoplastic (radioactive)

Description

Ibritumomab Tiuxetan (ib-ri-TU-moe-mab) (tie-ux-EH-tan) is a protein called a monoclonal antibody. It is used along with another monoclonal antibody (rituximab) and two radioactive pharmaceuticals (In-111 and Y-90). Ibritumomab tiuxetan is used to treat a type of cancer called non-Hodgkin's lymphoma.

Ibritumomab Tiuxetan is to be administered only by or under the immediate supervision of your doctor. It is available in the following dosage form:

Parenteral
• Injection (U.S.)

Brand Names

Some commonly used brand names are:

In the U.S. -

• Zevalin

Other commonly used names are:

• IDEC-2B8 (ibritumomab tiuxetan)
• IDEC-Y2B8 (yttrium-90-ibritumomab tiuxetan)
• IDEC-In2B8 (indium-111-ibritumomab tiuxetan)
• IDEC-129

† Not commercially available in Canada.